Comparative clinical study between roxithromycin and cephalexin in the treatment of folliculitis, furunculosis and Erysipelas/Cellulitis;ESTUDO CLINICO COMPARATIVO ENTRE ROXITROMICINA E CEFALEXINA NO TRATAMENTO DE FOLICULITE, FURUNCULOSE E ERISIPELA/CELULITE

Revista Brasileira de Medicina

Volumn 53, Issue 1-2, 1996, Pages 81-86

  Pereira, Luis Carlos ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; ROXITHROMYCIN;

ADULT; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERYSIPELAS; FEMALE; FOLLICULITIS; FURUNCULOSIS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0029882087     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. a-Ediçâo, págs. 277-9.
2. Herron, J.N. (1987); Roxithromycin in the Therapy of Streptococcus pyogens Throat Infections; J Antimicrob Chemoter 20 (suppl. B): 139-44.
3. Gasc, U.C.; Ambriiris, S.G.; Lutz, A. et al. (1991); The New Ether Oxime Derivatives of Erithromycin. A Structure Activity Relationship Study; The Journal of Antibiotics 314: 313-30.
4. Kafetzis, D.A.; Krotsi-Laskari, M.;Tremblay, D.; Salnt-Salvi, B. (1988); Multiple Dose Pharmacokinetics in Infants and Children Treated with Roxithromycm; Brit Journal of Clin Prac 42 (suppl. 55): 58.
5. Kees, F.; Grobecker, H.; Fourtillan, J.B. et al. (1988); Comparative Pharmacokinetics of Single Dose Roxithromycin (150 mg) versus Erythromycin Stearate (500 mg) in Healthy Volunteers; Brit Journal of Clin Prac 42 (Suppl. 55): 51.
6. Lassmann, H.B.; Puri, S.K.; Ho, I. et al. (1988); Pharmacokinetics of Roxithromycin (RU 965); J Clin Phamacol 28: 141-52.
7. Tremblay, D.; Jaeger, H.; Fourtillan, J.B. et al. (1988a); Pharmacokinetics of Three Single Doses (150, 300, 450 mg) of Roxithromycin in Young Volunteers, Brit Journal of Clin Prac 42 (suppl. 55): 49-50.
8. Halstenson, C.E.; Opsahl, J.A.; Schwenk, M.H. et al. (1990); Disposition of Roxithromycin in Patients with Normal and Severely Impaired Renal Function, Antimicrob Agents Chemoter 34: 385-9.
9. Birkett, D.J.; Robson, R.A.; Grgurinovich, N. et al. (1990); Single Oral Dose Pharmacokinetics of Erythromycin and Roxithromycin and the Effects of Chronic Dosing, Ther Drug Monit 12: 65-71.
10. Nilsen, O.G. (1987); Comparative Pharmacokinetics of Macrolides, J Antimicrob Chemoter 20 (suppl. B): 81-8.
11. Bergogne-Berezin, E. (1987); Tissue Distribution of Roxithromycin, J Antimicrob Chemoter 20 (suppl. B): 113-20.
12. Puri, S.K. & Lassman, H.B. (1987); Roxithromycin: A Pharmacokinetic Review of a Macrolide, J Antimicrobial Chemother 20 (Suppl. B): 89-100.
13. McLean, A ; Sutton, J.A.; Salmon, J. et al. (1988); Roxithromycin: Pharmacokinetic and Metabolism Study in Humans, BrJ Clin Pract 42 (suppl. 55): 52-3.
14. Griffith, R.S. (1983); The Pharmacology of Cephalexin, Postgrad Med J 59 (suppl. 5): 16-27.
15. Souza, E.M. & Silva, V.M.C.F. (1995); Estudo Clínico da Efetividade.Tblerabilidade e Aderência ao Tratamento das Infecçöes de Pele com Roxitromicma Comparada à Cefalexina, Rev Bras Med 52(7): 799-803.
16. Jardim, M.L. & Mendonça, M.G. (1995); O Tratamento de Infecções Cutâneas de Origem Bacteriana. Estudo Aberto, Randomizado, Comparativo entre Roxitromicina e Cefalexina, Rev Bras Med 52(9):1047-51.
17. Bazet, M.C.; Blanc, F.; Chumdermpadetsuk, S.; Fiessinger, S.; Kafetzis, D. et al. (1988); Roxithromycin in the Treatment of Paediatric Infections; Brit Journal of Clin Prac 42 (suppl. 55): 117-8.
18. Matsumoto, F. & Hara, K. (1987); Multicentre Clinical Studies of Roxilhromycin in Respiratory, otorhinolaryngological, Skin and Dental Infections, and Chlamydial Sexually Transmitted Diseases, 15th. International Congress of Chemotherapy, Istanbul, July 19-24, 1987.
19. Stamboulian, D.; Fernandez-McLoughlin, G.J.; Lanoël, J.L.; Sarachian, B. (1988); Clinical Evaluation of Roxithromycin in 101 Children, Brit Journal of Clin Prac 42 (suppl. 55): 115-6.
20. Segre, G.; Bianchi, E.; Zanolo, G.; Bartucci, F.; Sassella, D. (1988); Influence of Food on the Bioavailability of Roxithromycin Vs. Erythromycin Stearate; Brit Journal of Clin Prac 42 (suppl. 55): 55-7.
21. Pappalardo, G.; Rossetti, B.; Alessandra, S.; Greco, S.; Nicoletti, G.; Gismondo, M.R.; Lo Blue AM (1992); Roxithromycin in Dental Infections; Minerva Stomatol 41 (12): 377-81.
22. Demotes-Mainard, F.M.; Vincom, G.A.; Albin, H.C. (1989); Pharmacokinetics of a New Macrolide, Roxithromycin, in Infants and Children; J Clin Pharmacol 29: 752-6.
23. Nielsen, O.G.; Trond, A.; Zahlsen, K.; Svarva, P. (1992); Macrolide Pharmacokinetics and Dose Scheduling of Roxithromycin; Diagn Microbiol Infect Dis 15: 71S-76S.
24. DiMattia, A.F. et al. (1981); Efficacy of Two Dosage Schedules of Cephalexin in Dermatologic Infections; J Family Practice 12: 649-52.
25. Derrick, C.W, & Reilly, K. (1983); The Role of Cephalexin in the Treatment of Skin and Softtissue Infections; Postgrad Med J 59 (Suppl. 5): 43-6.